SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability
BackgroundOptimizing adjuvant is one of the critical methods to improve the vaccine. 3M-052, a novel TLR7/8 agonist which was designed for slow dissemination at the injection site, has a potential as adjuvant, but its performance as a vaccine adjuvant for SARS-CoV-2 (B.1.617.2) spike protein has not...
Saved in:
Main Authors: | Hong Huang (Author), Zhongcheng Zhou (Author), Xinxin Xiong (Author), Zhihai Liu (Author), Xiaoxue Zheng (Author), Qingli Quan (Author), Meixing Yu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is the Delta Plus Variant (B.1.617.2/AY1) more serious than the Delta Variant?
by: Mohana Priya Kunasekaran, et al.
Published: (2021) -
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
by: Manish Dhawan, et al.
Published: (2022) -
Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients
by: Miao Lai, et al.
Published: (2023) -
Effects of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) Delta variant (B.1.617.2) on maternal and neonatal outcomes
by: Kalsang Dolma, et al.
Published: (2023) -
Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study
by: Hester Allen, et al.
Published: (2022)